Cardiovascular Specialist
Brigham and Women's Hospital
Boston, Massachusetts, United States
Peter Libby, MD, is a cardiovascular specialist at Brigham and Women’s Hospital in Boston, Massachusetts, and holds the Mallinckrodt Professorship of Medicine at Harvard Medical School. He served as Chief of Cardiovascular Medicine at BWH from 1998-2014. His areas of clinical expertise include general and preventive cardiology. His current major research focus is the role of inflammation in vascular diseases such as atherosclerosis. Dr. Libby has a particular devotion to translate his basic laboratory studies to pilot and then large-scale clinical cardiovascular outcome trials.
An author and lecturer on cardiovascular medicine and atherosclerosis, Dr. Libby has published extensively in medical journals He is an Editor of Braunwald’s Heart Disease. He has held numerous visiting professorships and delivered more than 150 major named or keynote lectures throughout the world.
Saturday, February 25, 2023
1:45 PM – 2:00 PM ET
Disclosure information not submitted.
Saturday, February 25, 2023
2:32 PM – 2:40 PM ET
Disclosure(s): Amgen: Scientific Advisory Board (Ongoing), unpaid consultant to, or involved in clinical trials for (Ongoing); AstraZeneca: unpaid consultant to, or involved in clinical trials for (Ongoing); Baim Institute for Clinical Research: unpaid consultant to, or involved in clinical trials for (Ongoing); Beren Therapeutics: unpaid consultant to, or involved in clinical trials for (Ongoing); Caristo Diagnostics: Scientific Advisory Board (Ongoing); Cartesian Therapeutics: Scientific Advisory Board (Ongoing); CSL Behring: Scientific Advisory Board (Ongoing); DalCor Pharmaceuticals: Scientific Advisory Board (Ongoing); Dewpoint Therapeutics: Scientific Advisory Board (Ongoing); Esperion Therapeutics: unpaid consultant to, or involved in clinical trials for (Ongoing); Genentech: unpaid consultant to, or involved in clinical trials for (Ongoing); Kancera: Scientific Advisory Board (Ongoing), unpaid consultant to, or involved in clinical trials for (Ongoing); Kowa Pharmaceuticals: Scientific Advisory Board (Ongoing), unpaid consultant to, or involved in clinical trials for (Ongoing); MedImmune: Scientific Advisory Board (Ongoing), unpaid consultant to, or involved in clinical trials for (Ongoing); Merck: unpaid consultant to, or involved in clinical trials for (Ongoing); Norvo Nordisk: unpaid consultant to, or involved in clinical trials for (Ongoing); Novartis: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Scientific Advisory Board (Ongoing), unpaid consultant to, or involved in clinical trials for (Ongoing); Olatec Therapeutics: Scientific Advisory Board (Ongoing); Pfizer: unpaid consultant to, or involved in clinical trials for (Ongoing); PlaqueTec Ltd: Scientific Advisory Board (Ongoing); Sanofi-Regeneron: unpaid consultant to, or involved in clinical trials for (Ongoing); Soley Thereapeutics: Scientific Advisory Board (Ongoing); TenSixteen Bio: Scientific Advisory Board (Ongoing); XBiotech, Inc.: Board Member (Ongoing)
Saturday, February 25, 2023
2:56 PM – 3:11 PM ET
Disclosure(s): Amgen: Scientific Advisory Board (Ongoing), unpaid consultant to, or involved in clinical trials for (Ongoing); AstraZeneca: unpaid consultant to, or involved in clinical trials for (Ongoing); Baim Institute for Clinical Research: unpaid consultant to, or involved in clinical trials for (Ongoing); Beren Therapeutics: unpaid consultant to, or involved in clinical trials for (Ongoing); Caristo Diagnostics: Scientific Advisory Board (Ongoing); Cartesian Therapeutics: Scientific Advisory Board (Ongoing); CSL Behring: Scientific Advisory Board (Ongoing); DalCor Pharmaceuticals: Scientific Advisory Board (Ongoing); Dewpoint Therapeutics: Scientific Advisory Board (Ongoing); Esperion Therapeutics: unpaid consultant to, or involved in clinical trials for (Ongoing); Genentech: unpaid consultant to, or involved in clinical trials for (Ongoing); Kancera: Scientific Advisory Board (Ongoing), unpaid consultant to, or involved in clinical trials for (Ongoing); Kowa Pharmaceuticals: Scientific Advisory Board (Ongoing), unpaid consultant to, or involved in clinical trials for (Ongoing); MedImmune: Scientific Advisory Board (Ongoing), unpaid consultant to, or involved in clinical trials for (Ongoing); Merck: unpaid consultant to, or involved in clinical trials for (Ongoing); Norvo Nordisk: unpaid consultant to, or involved in clinical trials for (Ongoing); Novartis: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Scientific Advisory Board (Ongoing), unpaid consultant to, or involved in clinical trials for (Ongoing); Olatec Therapeutics: Scientific Advisory Board (Ongoing); Pfizer: unpaid consultant to, or involved in clinical trials for (Ongoing); PlaqueTec Ltd: Scientific Advisory Board (Ongoing); Sanofi-Regeneron: unpaid consultant to, or involved in clinical trials for (Ongoing); Soley Thereapeutics: Scientific Advisory Board (Ongoing); TenSixteen Bio: Scientific Advisory Board (Ongoing); XBiotech, Inc.: Board Member (Ongoing)
Saturday, February 25, 2023
4:46 PM – 4:54 PM ET
Disclosure(s): Amgen: Scientific Advisory Board (Ongoing), unpaid consultant to, or involved in clinical trials for (Ongoing); AstraZeneca: unpaid consultant to, or involved in clinical trials for (Ongoing); Baim Institute for Clinical Research: unpaid consultant to, or involved in clinical trials for (Ongoing); Beren Therapeutics: unpaid consultant to, or involved in clinical trials for (Ongoing); Caristo Diagnostics: Scientific Advisory Board (Ongoing); Cartesian Therapeutics: Scientific Advisory Board (Ongoing); CSL Behring: Scientific Advisory Board (Ongoing); DalCor Pharmaceuticals: Scientific Advisory Board (Ongoing); Dewpoint Therapeutics: Scientific Advisory Board (Ongoing); Esperion Therapeutics: unpaid consultant to, or involved in clinical trials for (Ongoing); Genentech: unpaid consultant to, or involved in clinical trials for (Ongoing); Kancera: Scientific Advisory Board (Ongoing), unpaid consultant to, or involved in clinical trials for (Ongoing); Kowa Pharmaceuticals: Scientific Advisory Board (Ongoing), unpaid consultant to, or involved in clinical trials for (Ongoing); MedImmune: Scientific Advisory Board (Ongoing), unpaid consultant to, or involved in clinical trials for (Ongoing); Merck: unpaid consultant to, or involved in clinical trials for (Ongoing); Norvo Nordisk: unpaid consultant to, or involved in clinical trials for (Ongoing); Novartis: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Scientific Advisory Board (Ongoing), unpaid consultant to, or involved in clinical trials for (Ongoing); Olatec Therapeutics: Scientific Advisory Board (Ongoing); Pfizer: unpaid consultant to, or involved in clinical trials for (Ongoing); PlaqueTec Ltd: Scientific Advisory Board (Ongoing); Sanofi-Regeneron: unpaid consultant to, or involved in clinical trials for (Ongoing); Soley Thereapeutics: Scientific Advisory Board (Ongoing); TenSixteen Bio: Scientific Advisory Board (Ongoing); XBiotech, Inc.: Board Member (Ongoing)
Saturday, February 25, 2023
5:26 PM – 5:35 PM ET
Disclosure(s): Amgen: Scientific Advisory Board (Ongoing), unpaid consultant to, or involved in clinical trials for (Ongoing); AstraZeneca: unpaid consultant to, or involved in clinical trials for (Ongoing); Baim Institute for Clinical Research: unpaid consultant to, or involved in clinical trials for (Ongoing); Beren Therapeutics: unpaid consultant to, or involved in clinical trials for (Ongoing); Caristo Diagnostics: Scientific Advisory Board (Ongoing); Cartesian Therapeutics: Scientific Advisory Board (Ongoing); CSL Behring: Scientific Advisory Board (Ongoing); DalCor Pharmaceuticals: Scientific Advisory Board (Ongoing); Dewpoint Therapeutics: Scientific Advisory Board (Ongoing); Esperion Therapeutics: unpaid consultant to, or involved in clinical trials for (Ongoing); Genentech: unpaid consultant to, or involved in clinical trials for (Ongoing); Kancera: Scientific Advisory Board (Ongoing), unpaid consultant to, or involved in clinical trials for (Ongoing); Kowa Pharmaceuticals: Scientific Advisory Board (Ongoing), unpaid consultant to, or involved in clinical trials for (Ongoing); MedImmune: Scientific Advisory Board (Ongoing), unpaid consultant to, or involved in clinical trials for (Ongoing); Merck: unpaid consultant to, or involved in clinical trials for (Ongoing); Norvo Nordisk: unpaid consultant to, or involved in clinical trials for (Ongoing); Novartis: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Scientific Advisory Board (Ongoing), unpaid consultant to, or involved in clinical trials for (Ongoing); Olatec Therapeutics: Scientific Advisory Board (Ongoing); Pfizer: unpaid consultant to, or involved in clinical trials for (Ongoing); PlaqueTec Ltd: Scientific Advisory Board (Ongoing); Sanofi-Regeneron: unpaid consultant to, or involved in clinical trials for (Ongoing); Soley Thereapeutics: Scientific Advisory Board (Ongoing); TenSixteen Bio: Scientific Advisory Board (Ongoing); XBiotech, Inc.: Board Member (Ongoing)